Paromomycin
- Generic Name
- Paromomycin
- Brand Names
- Humatin
- Drug Type
- Small Molecule
- Chemical Formula
- C23H45N5O14
- CAS Number
- 7542-37-2
- Unique Ingredient Identifier
- 61JJC8N5ZK
- Background
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
- Indication
For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
- Associated Conditions
- Dientamoeba fragilis infection, Hepatic coma, Acute Intestinal amebiasis, Chronic Intestinal amebiasis
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
- Conditions
- Visceral Leishmaniasis
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- PATH
- Target Recruit Count
- 120
- Registration Number
- NCT01328457
- Locations
- 🇧🇩
Bhaluka Upazila Health Complex, Bhaluka, Mymensingh District, Bangladesh
🇧🇩Trishal Upazila Health Complex, Trishal, Mymensingh District, Bangladesh
🇧🇩Icddr,B, Dhaka, Bangladesh
Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
- Conditions
- Leishmaniasis, Cutaneous
- Interventions
- Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Target Recruit Count
- 30
- Registration Number
- NCT01083576
- Locations
- 🇵🇦
Gorgas Memorial Institute Clinical Research Unit, Panama City, Panama
Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01050777
- Locations
- 🇮🇷
Emam Reza Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
- Conditions
- Leishmaniasis, Cutaneous
- Interventions
- Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Target Recruit Count
- 30
- Registration Number
- NCT01032382
- Locations
- 🇵🇪
Universidad Peruana Cayetano Heredia (UPCH), Lima, Peru
Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Target Recruit Count
- 1
- Registration Number
- NCT00657917
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2008-09-12
- Lead Sponsor
- Banaras Hindu University
- Target Recruit Count
- 329
- Registration Number
- NCT00629031
- Locations
- 🇮🇳
Kala-azar Medical Research Center, Rambag Road, Varanasi, India
Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Target Recruit Count
- 375
- Registration Number
- NCT00606580
- Locations
- 🇹🇳
Central Clinic-Sidi Bouzid, Tunis, Tunisia
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- PATH
- Target Recruit Count
- 2000
- Registration Number
- NCT00604955
- Locations
- 🇮🇳
Rajendra Memorial Research Institute of Medical Sciences, Agam Kuan, Patna, Bihar, India
🇮🇳Shrimati Hazari Maternity and Medical Care, Azad Nagar, Balua Tal, Motihari, Bihar, India
🇮🇳Research Centre for Diabetes, Hypertension and Obesity, Bengali Tola, Samastipur, Bihar, India
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
- Conditions
- Visceral Leishmaniasis
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 1142
- Registration Number
- NCT00255567
- Locations
- 🇺🇬
Amudat Hospital, Amudat, Nakipiripirit district, Uganda
🇰🇪KEMRI, Nairobi, Kenya
🇪🇹Arba Minch Hospital, Arba Minch, Ethiopia
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
- Conditions
- Visceral Leishmaniasis
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- PATH
- Target Recruit Count
- 667
- Registration Number
- NCT00216346
- Locations
- 🇮🇳
Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agam Kuan, Patna, Bihar, India
🇮🇳Kalazar Research Centre, Patna, Bihar, India
🇮🇳Kala-azar Medical Research Centre, Rambagh Road Muzaffarpur, Bihar, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.